Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

This article was originally published in The Pink Sheet Daily

Executive Summary

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

You may also be interested in...

Conceptus suit

In a lawsuit filed in Northern California federal court, the maker of the Essure non-incisional permanent birth control device alleges Hologic's Adiana permanent contraception system violates several patents held by Conceptus. The firm is seeking an injunction prohibiting Hologic from selling Adiana in the U.S., Conceptus says May 22. Adiana was deemed "approvable" by FDA in March, pending inspection of Hologic's Costa Rican facility. An FDA advisory panel voted to recommend approval of the product in late 2007 (1"The Gray Sheet" Dec. 17, 2007, p. 3). In 2002, Essure became the first permanent birth control device approved by FDA as an alternative to tubal ligation

Adiana Permanent Birth Control Device Endorsed By FDA Panel In 10-3 Vote

Hologic's Adiana permanent female birth control system should be approved by FDA, contingent upon a postmarket study comparing the device with an alternative method of permanent female birth control, the agency's Obstetrics and Gynecology Devices Panel recommended Dec. 13

MADIT-CRT Data Support Expanded Cardiac Resynchronization Market

The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts